Subramani, Ramadevi Chatterjee, Animesh Pedroza, Diego A. Poudel, Seeta Rajkumar, Preetha Annabi, Jeffrey Penner, Elizabeth Lakshmanaswamy, Rajkumar
Published in
Frontiers in Oncology
Background Triple-negative breast cancer (TNBC) is a subtype of breast cancer with no effective targeted treatment currently available. Estrogen and its metabolites influence the growth of mammary cancer. Previously, we demonstrated the anti-cancer effects of 2-methoxyestradiol (2ME2) on mammary carcinogenesis. Materials and methods In the present ...
Capatina, Alina L. Malcolm, Jodie R. Stenning, Jack Moore, Rachael L. Bridge, Katherine S. Brackenbury, William J. Holding, Andrew N.
Published in
Frontiers in Cell and Developmental Biology
Hypoxia-mediated epigenetic regulation of breast cancer progression.
Alharbi, Malak Roy, Arya Mariam Krishnan, Jayasree Kalinski, Pawel Yao, Song Gandhi, Shipra
Published in
Frontiers in Immunology
Triple negative breast cancer (TNBC) is a heterogenous disease that disproportionately affects Black women. TNBC outcomes among Black women are dismal secondary to multiple factors, such as poor healthcare accessibility resulting in delays in diagnosis, and aggressive disease biology in addition to a pro-tumor immune microenvironment (TME). Black w...
Wang, Zheng Li, Anqi Lu, Yujie Han, Mengyuan Ruan, Miao Wang, Chaofu Zhang, Xiaotian Zhu, Changbin Shen, Kunwei Dong, Lei
...
Published in
Frontiers in Immunology
The aim of this study was to evaluate the mutation spectrum of homologous recombination repair (HRR) genes and its association with tumor immune infiltration and prognosis in triple-negative breast cancer (TNBC). TNBC patients (434 patients from Ruijin cohort) were evaluated with targeted next-generating sequencing for mutations in HRR genes. The f...
Dhanalakshmi, Boregowda Anil Kumar, Belagal Motatis Srinivasa Murthy, Venkatappan Srinivasa, Sudhanva Muddenahalli Vivek, Hamse Kameshwar Sennappan, Madhappan Rangappa, Shobith
Published in
Journal of biomolecular structure & dynamics
Novel 4-aminophenol benzamide-1,2,4 oxadiazole library of small molecules displayed potent antiproliferative activity.Compound 7k induces apoptosis significantly against triple-negative breast cancer cells.Compound 7k potentiates apoptosis by targeting MAPK P38 and altering mitochondrial membrane potential.Molecular docking and molecular dynamic si...
Vannini, Andrea Parenti, Federico Forghieri, Cristina Barboni, Catia Zaghini, Anna Campadelli-Fiume, Gabriella Gianni, Tatiana
Published in
Frontiers in Molecular Biosciences
Attia, Yasmeen Hakeem, Andrew Samir, Rawda Mohammed, Aya Elsayed, Abdullrahman Khallaf, Alaa Essam, Eman Amin, Hossameldeen Abdullah, Sarah Hikmat, Salwan
...
Published in
Frontiers in Pharmacology
Sympathetic activation triggered by chronic stress afflicting cancer survivors is an emerging modulator of tumorigenesis. Adrenergic blockade was previously associated with improving response to doxorubicin (DOX) in triple-negative breast cancer (TNBC), yet the precise underlying mechanisms remain obscure. The resilience of cancer stem cells (CSCs)...
Cui, Lishan Perini, Giordano Augello, Alberto Palmieri, Valentina De Spirito, Marco Papi, Massimiliano
Published in
Frontiers in Bioengineering and Biotechnology
Introduction: Triple negative breast cancer (TNBC), a highly aggressive subtype accounting for 15–20% of all breast cancer cases, faces limited treatment options often accompanied by severe side effects. In recent years, natural extracellular nanovesicles derived from plants have emerged as promising candidates for cancer therapy, given their safet...
Schroeder, Jade Polemi, Katelyn M. Tapaswi, Anagha Svoboda, Laurie K. Sexton, Jonathan Z. Colacino, Justin A.
Published in
Frontiers in Oncology
Introduction Breast cancer is the second most diagnosed cancer, as well as the primary cause of cancer death in women worldwide. Of the different breast cancer subtypes, triple-negative breast cancer (TNBC) is particularly aggressive and is associated with poor prognosis. Black women are two to three times more likely to be diagnosed with TNBCs tha...
Takchi, Andrew Zhang, Minzhi Jalalirad, Mohammad Ferre, Roberto Leon Shrestha, Royal Haddad, Tufia Sarkaria, Jann Tuma, Ann Carter, Jodi David, Hillman
...
Published in
Frontiers in Oncology
Triple negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and mainly affects pre-menopausal and minority women. Because of the lack of ER, PR or HER2 expression in TNBC, there are limited options for tailored therapies. While TNBCs respond initially to standard of care chemotherapy, tumor recurrence commonly occurs within 1 to ...
